-
AstraZeneca's has launched the type 2 diabetes drug Qtern in India, as reported in Fidelity.
-
In September, the company received the import and market permission from the Drugs Controller General of India for Qtern, a fixed-dose combination of dapagliflozin plus saxagliptin.
To read more NewsPoints articles, click here.
